PerkinElmer introduces no-wash immunoassay for mitophagy dysfunction

By The Science Advisory Board staff writers

October 27, 2020 -- PerkinElmer has debuted a no-wash ubiquitin phosphorylation at serine 65 immunoassay for studying defective mitophagy dysfunction associated with Parkinson's and Alzheimer's diseases.

Designed to help scientists discover new therapeutic candidates earlier in the disease cycle, the Cisbio HTRF Phospho-Ubiquitin (Ser65) Cellular Kit makes use of time-resolved fluorescence energy transfer (TR-FRET) technology and provides a "mix and read" approach, according to the company.

The immunoassay is compatible with microplate readers such as the firm's Victor Nivo or EnVision systems. Analysis can be automated and run in high-throughput formats, according to PerkinElmer.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.